Combination extends OS in metastatic colorectal cancer
The addition of bevacizumab to trifluridine and tipiracil extended OS among patients with advanced colorectal cancer, according to a topline data announcement.Trifluridine and tipiracil (Lonsurf; Taiho Oncology, Servier) is an oral agent that utilizes a dual mechanism of action to maintain clinical activity. Trifluridine, an antineoplastic nucleoside analogue, interferes with DNA function. The
Source: healio.com